Growth Factors & Signaling
Overview
Growth-hormone secretagogues and GHRH-receptor agonists — ghrelin-receptor peptides, the oral non-peptide secretagogue MK-677, and long- and short-acting GHRH analogues, with a comparison page.
| Compound | Class | Mechanism | Primary research targets |
|---|---|---|---|
| MK-677 (Ibutamoren) | Non-peptide GHSR agonist | GHSR-1a agonist (non-peptide) | Muscle growth, bone density, appetite |
| Ipamorelin | Pentapeptide GHSR agonist | Selective GHSR agonist | GH release, muscle repair, metabolism |
| GHRP-2 | Hexapeptide GHSR agonist | Potent GHSR agonist | GH pulse amplification, catabolic states |
| GHRP-6 | Hexapeptide GHSR agonist | First-generation GHRP | GH secretion, appetite stimulation |
| CJC-1295 | GHRH analogue (DAC) | GHRH analogue (DAC technology) | Sustained GH / IGF-1 elevation |
| Sermorelin | GHRH(1–29) fragment | GHRH(1–29) fragment | GH-deficiency and diagnostic research |
How Growth Signaling Peptides Work
Two receptor families dominate here. Ghrelin-receptor (GHSR-1a) agonists — the GHRPs, the selective peptide Ipamorelin and the oral non-peptide MK-677 — mimic ghrelin to trigger pulsatile growth-hormone release through Gαq and calcium signalling. GHRH-receptor agonists — Sermorelin (short-acting) and CJC-1295 (long-acting, DAC) — act like GHRH itself through Gαs and cAMP. A recurring research theme is pairing the two families for complementary GH release.
1. Growth-hormone-secretagogue (GHSR) pathway
MK-677, Ipamorelin and the GHRPs bind GHSR-1a (the ghrelin receptor), stimulating pituitary GH release via Gαq/Ca²⁺, while enhancing GHRH and inhibiting somatostatin.
2. GHRH-receptor pathway
CJC-1295 and Sermorelin activate the GHRH receptor (Gαs/cAMP), amplifying the amplitude and frequency of endogenous GH pulses.
3. GH → IGF-1 axis
All secretagogues raise circulating GH, which drives hepatic IGF-1 and downstream anabolic effects while preserving pulsatility.
Key Properties at a Glance
| Compound | CAS number | MW (Da) | Length | Mechanism | Half-life |
|---|---|---|---|---|---|
| MK-677 (Ibutamoren) | 159634-47-0 | 528.66 | — (non-peptide) | GHSR-1a agonist (non-peptide) | ~ 24 h |
| Ipamorelin | 170851-70-4 | 711.86 | 5 aa | Selective GHSR agonist | ~ 2 h |
| GHRP-2 | 158861-67-7 | ≈ 817.9 | 6 aa | Potent GHSR agonist | ~ 30 min |
| GHRP-6 | 87616-84-0 | 873.01 | 6 aa | First-generation GHRP | ~ 30 min |
| CJC-1295 | 863288-34-8 | ≈ 3647 (DAC) | 29–30 aa | GHRH analogue (DAC technology) | ~ 6–8 days |
| Sermorelin | 86168-78-7 | ≈ 3357.9 | 29 aa | GHRH(1–29) fragment | ~ 12 min |
Research Evidence Summary
Representative reported findings from the literature (qualitative). See each compound page for detail.
| Compound | Key reported finding | Reference |
|---|---|---|
| MK-677 | Increased 24-h GH and IGF-1 | Chapman IM et al. |
| MK-677 | Increased lean mass and bone density over 2 years | Nass R et al., 2008 |
| MK-677 | Preserved GH pulsatility with oral, once-daily dosing | MK-677 literature |
| Ipamorelin | Potent, selective GH release with minimal prolactin/cortisol | Raun K et al. |
| Ipamorelin | Bone-formation markers in ovariectomized models | GH-secretagogue literature |
| GHRP-2 | Strong GH pulse amplification (high potency) | Bowers CY et al. |
| GHRP-2 | Used as a GH-reserve diagnostic probe | GHRP-2 clinical literature |
| GHRP-6 | First peptide GH secretagogue shown to be orally active | Bowers CY et al. |
| GHRP-6 | Strong ghrelin-appetite signalling | GHRP-6 literature |
| CJC-1295 | Sustained GH/IGF-1 elevation over several days | Teichman SL et al., 2006 |
| CJC-1295 | DAC albumin binding extends half-life to ~6–8 days | GHRH-analogue literature |
| Sermorelin | Reliable GH release; used in GH-deficiency testing | GHRH literature |
| Sermorelin | Physiological, short-acting GHRH-receptor probe | GHRH literature |
Research Dosing Overview
Typical research dose ranges from the literature (for research reference only, not human dosing guidance):
| Compound | Research dose | Route | Frequency | Duration |
|---|---|---|---|---|
| MK-677 (Ibutamoren) | 10–25 mg | Oral | Daily | 12–52 wk |
| Ipamorelin | 200–500 µg | SC | 2–3×/day | 8–16 wk |
| GHRP-2 | 100–300 µg | SC | 2–3×/day | 8–16 wk |
| GHRP-6 | 100–300 µg | SC | 2–3×/day | 8–16 wk |
| CJC-1295 | 1–2 mg | SC | Every 5–8 d | 8–16 wk |
| Sermorelin | 200–500 µg | SC / IV | Daily | 12–24 wk |
Formulation & Reconstitution
| Factor | Recommendation |
|---|---|
| Solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution | 1–2 mL per vial (peptide-dependent) |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
| Storage (reconstituted) | 2–8°C for up to 7–14 days |
| pH stability range | 5.0–7.0 |
| Oxidation-sensitive residues | Protect Met / Cys peptides from air and light; add antioxidant where relevant |
Selected References
- Bowers CY. Growth-hormone-releasing peptide (GHRP) foundational literature.
- Raun K, et al. Ipamorelin, a selective GH secretagogue. European Journal of Endocrinology.
- Teichman SL, et al. Long-acting GHRH analogue CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- Nass R, et al. Oral ghrelin mimetic MK-677 and body composition. Annals of Internal Medicine, 2008.
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
